At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01877 JUNSHI BIO
Trading 06-17 14:09:11
15.920
-0.590
-3.57%
High16.640
Low15.910
Vol1.57M
Open16.350
D1 Closing16.510
Amplitude4.42%
Mkt Cap16.35B
Tradable Cap4.14B
Total Shares1.03B
T/O25.37M
T/O Rate0.60%
Tradable Shares260.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
JUNSHI BIO Shares Surge Over 5% Following Strategic Investment in Shanghai Biopharma Firm for ADC and Multispecific Antibody Development
JUNSHI BIO Tables AGM Agenda: No 2025 Dividend, Up to RMB8.50 Billion Credit, RMB5.00 Billion Guarantee Quota and Fresh Mandates for Debt and Share Issuance
Junshi BIO to Contribute Patent Equipment Valued at RMB 53.08 Million for Stake in Shanghai Zhiyu Biopharma, Expanding into ADC and Multi-Specific Antibody R&D
JUNSHI BIO (01877): Phase III Study of Toripalimab with Chemotherapy in Perioperative Treatment for Resectable Stage II-III Non-Small Cell Lung Cancer Meets Primary Endpoints in Final Analysis
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.